QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Romiplostim, Thrombopoietin-Receptor Biology, ITP, and Product Pharmacovigilance

Test your understanding of the concepts covered by Romiplostim: thrombopoietin receptor biology, immune thrombocytopenia, and product pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best explains why increased platelet production can benefit a patient whose autoimmune platelet destruction continues?

The production increase can exceed the rate of platelet clearance, raising the circulating count. Romiplostim prevents all immune recognition of platelets. Autoimmune destruction stops automatically once MPL is activated. New platelets are immune to all forms of clearance.

Question 2 of 10 Why should a medication-error report be retained for aggregate surveillance even if no adverse event occurred?

Because every medication error confirms product causality. Because repeated errors may reveal a preventable system weakness before clinical harm accumulates. Because medication errors are always more serious than adverse drug reactions. Because an error without harm must be coded as thrombosis.

Question 3 of 10 Which feature distinguishes romiplostim from endogenous thrombopoietin and reduces the theoretical risk of neutralising native TPO?

Romiplostim does not bind MPL. Romiplostim has no amino-acid sequence homology with endogenous TPO in its receptor-binding peptides. Romiplostim suppresses endogenous TPO production. Romiplostim is administered only by the oral route.

Question 4 of 10 Why is confirmation of the underlying diagnosis particularly important before using romiplostim in an older patient with thrombocytopenia?

Because ITP can only occur in children. Because myelodysplastic syndromes can also cause thrombocytopenia and have a different biological and regulatory context. Because romiplostim is contraindicated in all adults. Because platelet counts cannot be measured reliably in older people.

Question 5 of 10 What is the most appropriate treatment target when titrating romiplostim in ITP?

The highest platelet count achievable. A permanently normal platelet count in every patient. A platelet count sufficient to reduce clinically important bleeding risk while limiting excessive stimulation. A single platelet value within the laboratory reference interval.

Question 6 of 10 What is the principal functional contribution of romiplostim's Fc component?

It recognises the thrombopoietin receptor through antibody variable regions. It neutralises platelet autoantibodies. It increases molecular size and contributes to persistence in circulation. It activates T-cell immunity against autoreactive B cells.

Question 7 of 10 A patient's platelet count falls after corticosteroids are tapered while romiplostim dosing remains unchanged. What is the most appropriate interpretation?

The fall must be caused by romiplostim because its dose did not change. The timing of the concomitant-treatment change could explain the platelet trajectory and must be considered in causality assessment. The fall proves anti-romiplostim antibodies are present. The fall demonstrates that platelet production is independent of immune activity.

Question 8 of 10 Why does a normal platelet count at the time of a thrombotic event not exclude a possible contribution from romiplostim?

Because platelet counts are unrelated to romiplostim pharmacodynamics. Because the product information recognises thrombotic events can occur regardless of platelet count. Because all thromboses in ITP are caused by romiplostim. Because a normal count proves that the event is unrelated to the disease.

Question 9 of 10 Which feature makes paediatric pharmacovigilance for romiplostim especially dependent on accurate exposure documentation?

Children do not require platelet monitoring. Paediatric dosing is fixed and does not depend on body weight. Body weight changes, very small doses may require dilution, and self-administration is not permitted under the cited EU information. Paediatric patients cannot experience medication errors.

Question 10 of 10 Which information is most important for distinguishing a prescribed dose from the dose actually delivered in a suspected medication-error case?

The patient's age alone. The product's ATC code alone. The weight used, reconstitution and dilution steps, calculated volume, and administration records. The most recent platelet count without preparation details.

Knowledge Assessment: Romiplostim, Thrombopoietin-Receptor Biology, ITP, and Product Pharmacovigilance

Cookie Settings